We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.825 | 0.80 | 0.85 | 0.85 | 0.80 | 0.80 | 3,285,001 | 15:54:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.44 | 1.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/4/2018 09:56 | If you look at N4`s patent for Sildenafil, there is a long list of conditions that Sildenafil can be used for. As per my last link we can now include Cancer in that list. | hughwilson | |
13/4/2018 09:19 | This is targeting a breakout above 30p. Can you send me also the message hughwilson. Thanks. | escapetohome | |
13/4/2018 09:07 | Parob I will PM you. | hughwilson | |
13/4/2018 09:02 | Hopefully so Parob! | escapetohome | |
13/4/2018 08:53 | So we seem to have turned ready for the next leg up. | parob | |
12/4/2018 08:55 | Not selling even 0.000000000000001 of a share from my swiss deposit box. Not at this price. | escapetohome | |
12/4/2018 08:23 | Come on now n4p !!! BLUE FINISH!!!!!!!! | escapetohome | |
11/4/2018 20:21 | Sildenafil now to be used in the treatment of cancer. | hughwilson | |
11/4/2018 14:39 | So what happened to the commentators such as Ch1rp et al today? Apparently this had "strong support at this level (25p)" yesterday. It was also "moving along nicely" according to another.. Honestly it would be much better if you could bite your tongues and just keep quiet because you've all got a terrible case of commentators curse.. | dplewis1 | |
11/4/2018 12:30 | Be interesting to see what and who comes to the table at that point. My own thoughts were that Sildenafil may provide a quick revenue stream to allow nuvec and others to be developed to full potential. | tp6 | |
11/4/2018 08:45 | hi all - all depends on the mkt cap and fund options at the time. id we are £40 mil plus them personally i would like to go it alone | urigem | |
10/4/2018 21:50 | tp6, Nigels preference according to the last presentation would be to go it alone and get the 12% royalty as opposed the 5% with a JV. | hughwilson | |
10/4/2018 21:00 | Assuming decent or promising Sildenafil results, can anyone suggest a likely next step?I can guess at a few but am no pharmacutical expert..... | tp6 | |
10/4/2018 19:38 | Let's get the Sildenafil results first but the difference in royalties between being partnered and going it alone is 12% royalty as opposed to 5%. In a market worth billions of dollars you can see the difference it would make to N4. In my opinion, trials should be a success and if they are then the market will begin to sense the magnitude of what those results mean to the share price Fingers crossed but if results prove positive then we should see some amazing returns in the near term | hughwilson | |
10/4/2018 18:14 | Sometimes its good to re read some of the old stuff. | hughwilson | |
10/4/2018 12:46 | Strong support at this level. Everyone is aware of the potential here:))) | ch1rp | |
10/4/2018 09:49 | sorry, those little flurry of sells were my ST trading shares i bought back at 19p.. nice £9k profit in the bin for the summer hol's :-) Onwards and upwards | urigem | |
10/4/2018 09:29 | YEP, NICELY MOVING ALONG | urigem | |
10/4/2018 09:22 | Nice opening | qs99 | |
09/4/2018 16:16 | Ok maybe not today, but strong start to what I'm sure will be a good week for N4P:))) | ch1rp | |
09/4/2018 15:11 | 28p today:)))) | ch1rp | |
09/4/2018 11:58 | Well presumably the tests on humans have started and if it is having the desired effect then I’m pretty sure that the news will spread pretty rapidly. | jakleeds |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions